Latest Patents News

Elsight Limited (ASX:ELS) has shattered its revenue records in H1 2026, delivering a nearly fourfold increase over the prior year alongside expanding US defence contracts and new product launches.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Aruma Resources has launched a 3,600m Phase 2 diamond drilling program at its Tillex Copper-Silver Project in Ontario’s Timmins district, targeting extensions of a high-grade mineralised system identified in Phase 1.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

Pure Resources has achieved a key early milestone with Oak Ridge National Laboratory confirming the recovery of heavy rare earth elements from garnet concentrate at its Garnet Hills Project. While still at proof-of-concept stage, this validates the potential for a new source of critical minerals.

ClearVue Technologies has exceeded its $1 million target in a Share Purchase Plan, raising $1.29 million and issuing over 14.6 million shares with free attaching options pending shareholder approval.

Hydrix has landed a A$3.4 million contract with US-based Remedy Robotics to develop safety-critical software and embedded electronics for the N1 robotic system, marking a major step in its medical robotics ambitions.

Entropy Neurodynamics has expanded its global intellectual property portfolio with a South African patent for psilocybin-based fibromyalgia treatment, covering broad therapeutic methods and extending protection to 2043.

Hazer Group has completed a key commercial-scale hydrogen process design package with KBR, boosting its readiness for large-scale deployment and expanding its project pipeline across multiple sectors and geographies.

Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.

Titomic Limited updates investors that its planned shift of corporate domicile from Australia to the US is still underway but the timeline has slipped, with a revised schedule expected by late July or August 2026.

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.